KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Income from Continuing Operations: 2009-2025

Historic Income from Continuing Operations for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Sep 2025 value amounting to $1.5 billion.

  • Regeneron Pharmaceuticals' Income from Continuing Operations rose 8.91% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 billion, marking a year-over-year decrease of 1.64%. This contributed to the annual value of $4.4 billion for FY2024, which is 11.61% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Income from Continuing Operations stood at $1.5 billion for Q3 2025, which was up 4.92% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Income from Continuing Operations registered a high of $3.1 billion during Q2 2021, and its lowest value of $722.0 million during Q1 2024.
  • For the 3-year period, Regeneron Pharmaceuticals' Income from Continuing Operations averaged around $1.1 billion, with its median value being $1.0 billion (2023).
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first surged by 245.36% in 2021, then slumped by 72.50% in 2022.
  • Quarterly analysis of 5 years shows Regeneron Pharmaceuticals' Income from Continuing Operations stood at $2.2 billion in 2021, then plummeted by 46.29% to $1.2 billion in 2022, then declined by 3.13% to $1.2 billion in 2023, then decreased by 20.86% to $917.7 million in 2024, then rose by 8.91% to $1.5 billion in 2025.
  • Its Income from Continuing Operations stands at $1.5 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $808.7 million for Q1 2025.